Vidarabine

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Vidarabine is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1976. DrugCentral lists 10 molecular targets, including DPP4, Ahcy and Adcy5. Recorded indications include Herpes simplex dendritic keratitis and Herpes simplex keratitis.

• Approval status: ofm (first approved 1976 by the FDA).
• Molecular targets: DPP4, Ahcy, Adcy5 and RRM1 (10 listed in DrugCentral).
• Indications: Herpes simplex dendritic keratitis and Herpes simplex keratitis.
• ATC code: J05AB03 (Nucleosides and nucleotides excl. reverse transcriptase inhibitors).
• Molecular formula: C10H13N5O4; molecular weight 267.25 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Herpes simplex dendritic keratitis
• Herpes simplex keratitis

Mechanism & targets

Molecular targets (10)

Target	Gene	Action	Activity
Dipeptidyl peptidase 4	DPP4	unknown	IC50 7.21
Adenosylhomocysteinase	Ahcy	unknown	Ki 4.52
Adenylate cyclase type V	Adcy5	unknown	IC50 4.09
Ribonucleoside-diphosphate reductase large subunit	RRM1	unknown	—
Ribonucleoside-diphosphate reductase subunit M2	RRM2	unknown	—
DNA polymerase catalytic subunit	—	inhibitor	—
Ribose-phosphate pyrophosphokinase 1	PRPS1	unknown	—
Deoxyguanosine kinase, mitochondrial	DGUOK	unknown	—
Deoxycytidine kinase	DCK	unknown	—
DNA polymerase alpha catalytic subunit	POLA1	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1976-11-26	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
J05AB03	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Nucleosides and nucleotides excl. reverse transcriptase inhibitors
S01AD06	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antivirals

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Toxic encephalopathy	54.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vidarabine is on its molecule page.

• Molecular formula: C₁₀H₁₃N₅O₄
• Molecular weight: 267.25 g/mol
• CAS number: 5536-17-4
• InChIKey: OIRDTQYFTABQOQ-UHTZMRCNSA-N
• PubChem CID: 21704

NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vidarabine used for?

DrugCentral lists the following indications for Vidarabine: Herpes simplex dendritic keratitis and Herpes simplex keratitis.

How does Vidarabine work?

Its molecular targets in DrugCentral include DPP4, Ahcy, Adcy5 and RRM1.

When was Vidarabine first approved?

Vidarabine was first approved by the FDA in 1976.

What is the chemical formula of Vidarabine?

Vidarabine has the molecular formula C10H13N5O4 and a molecular weight of 267.25 g/mol.

Sources

• DrugCentral drug card 2818 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1090 — compound record and bioactivity
• PubChem CID 21704 — chemical identifiers
• DrugBank DB00194 — drug record
• FDA UNII FA2DM6879K — substance identity
• DailyMed: FDA labels for Vidarabine — current prescribing information (label search)
• UniProt P27487 (DPP4) — target protein
• UniProt P23921 (RRM1) — target protein
• UniProt P31350 (RRM2) — target protein
• UniProt P60891 (PRPS1) — target protein
• UniProt Q16854 (DGUOK) — target protein
• UniProt P27707 (DCK) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.